Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Amivantamab-vmjw + Capmatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Amivantamab-vmjw||Rybrevant||JNJ-61186372||EGFR Antibody 52 MET Antibody 26||Rybrevant (amivantamab-vmjw) is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193, PMID: 32414908). Rybrevant (amivantamab-vmjw) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy (FDA.gov).|
|Capmatinib||Tabrecta||INC280|INC-280|INCB028060|INCB28060|INCB 28060||MET Inhibitor 58||Tabrecta (capmatinib) inhibits MET signaling and may induce cell death in tumors overexpressing MET or expressing constitutively activated MET (PMID: 31853265). Tabrecta (capmatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05488314||Phase II||Amivantamab-vmjw + Capmatinib||A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark)||Recruiting||USA||2|